HHLR Advisors, Ltd. 13D and 13G filings for Aligos Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-02-14 4:37 pm Purchase |
2023-12-31 | 13G | Aligos Therapeutics, Inc. ALGS |
HHLR Advisors, Ltd. | 238,857 8.200% |
146,466 (+158.53%) |
Filing |
| 2023-02-14 4:10 pm Sale |
2022-12-31 | 13G | Aligos Therapeutics, Inc. ALGS |
HHLR Advisors, Ltd. | 92,391 5.800% |
-2,212 (-2.34%) |
Filing |
| 2022-02-14 4:08 pm Purchase |
2021-12-31 | 13G | Aligos Therapeutics, Inc. ALGS |
HHLR Advisors, Ltd. | 94,603 5.600% |
8,000 (+9.24%) |
Filing |
| 2021-02-16 4:27 pm Purchase |
2020-12-31 | 13G | Aligos Therapeutics, Inc. ALGS |
HHLR Advisors, Ltd. | 86,603 5.700% |
86,603 (New Position) |
Filing |